Mahal Jeetinder Singh 4

What Happened

• Mahal Jeetinder Singh, CEO, President and Director of Jasper Therapeutics (JSPR), was granted 500,000 derivative shares as an award on February 6, 2026. The reported acquisition price is $0.00 (no cash paid reported). The filing lists the transaction as an award/derivative (code A).

Key Details

• Transaction date: 2026-02-06; Form 4 filed 2026-02-10 (within the standard 2 business-day filing window).
• Quantity and price: 500,000 derivative shares acquired at $0.00; total cash amount reported $0.00.
• Shares owned after transaction: Not disclosed in the excerpt provided.
• Vesting footnote: 1/4 of the shares vest on Feb 6, 2027 (125,000 shares); thereafter 1/48th of the original grant vests each month (about 10,417 shares/month) until fully vested — i.e., monthly vesting over the following 36 months.
• Footnote code: A = Award/Grant of derivative securities.

Context

• This is a compensation-related award (derivative grant) rather than an open-market purchase or sale. Such awards are common for executives and reflect equity compensation and retention terms; they do not by themselves indicate a buy or sell market signal.
• The filing does not state whether the award is structured as RSUs, stock options, or another derivative form; it simply reports a derivative award with a specified vesting schedule.